The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

  • Authors:
    • Liang Liu
    • Jinfeng Xiang
    • Rufu Chen
    • Deliang Fu
    • Defei Hong
    • Jihui Hao
    • Yixiong Li
    • Jiangtao Li
    • Shengping Li
    • Yiping Mou
    • Gang Mai
    • Quanxing Ni
    • Li Peng
    • Renyi Qin
    • Honggang Qian
    • Chenghao Shao
    • Bei Sun
    • Yongwei Sun
    • Min Tao
    • Bole Tian
    • Hongxia Wang
    • Jian Wang
    • Liwei Wang
    • Wei Wang
    • Weilin Wang
    • Jun Zhang
    • Gang Zhao
    • Jun Zhou
    • Xianjun Yu
  • View Affiliations

  • Published online on: December 30, 2015     https://doi.org/10.3892/ijo.2015.3316
  • Pages: 900-907
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The prognosis for pancreatic cancer (PC) is poor; however, the timely and accurate treatment of this disease will significantly improve prognosis. Serum biomarkers involve non-invasive tests that facilitate the early detection of tumors, predict outcomes and assess responses to therapy, so that the patient can be continuously monitored and receive the most appropriate therapy. Studies have reported that cancer antigen (CA)125 [also known as mucin 16 (MUC16)] has functional significance in the tumorigenic, metastatic and drug resistant properties of PC. Our aim was to use this biomarker in the diagnosis, detection of metastasis, prognosis and in the monitoring of the treatment effects of PC. Members of the Chinese Study Group for Pancreatic Cancer (CSPAC) reviewed the literature on CA125/MUC16 and developed an objective consensus on the clinical utility of CA125/MUC16 for PC. They confirmed the role of CA125/MUC16 in tumorigenesis and the progression of PC, and recommended monitoring CA125/MUC16 levels in all aspects of the diagnosis and treatment of PC, particularly those that involve the monitoring of treatments. In addition, they suggested that the combination of other biomarkers and imaging techniques, together with CA125/MUC16, would improve the accuracy of the clinical decision-making process, thereby facilitating the optimization of treatment strategies. Periodic clinical updates of the use of CA125/MUC16 have been established, which are important for further analyses and comparisons of clinical results from affiliates and countries, particularly as regards the in-depth biological function and clinical translational research of this biomarker.
View References

Related Articles

Journal Cover

March 2016
Volume 48 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, L., Xiang, J., Chen, R., Fu, D., Hong, D., Hao, J. ... Yu, X. (2016). The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC). International Journal of Oncology, 48, 900-907. https://doi.org/10.3892/ijo.2015.3316
MLA
Liu, L., Xiang, J., Chen, R., Fu, D., Hong, D., Hao, J., Li, Y., Li, J., Li, S., Mou, Y., Mai, G., Ni, Q., Peng, L., Qin, R., Qian, H., Shao, C., Sun, B., Sun, Y., Tao, M., Tian, B., Wang, H., Wang, J., Wang, L., Wang, W., Wang, W., Zhang, J., Zhao, G., Zhou, J., Yu, X."The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)". International Journal of Oncology 48.3 (2016): 900-907.
Chicago
Liu, L., Xiang, J., Chen, R., Fu, D., Hong, D., Hao, J., Li, Y., Li, J., Li, S., Mou, Y., Mai, G., Ni, Q., Peng, L., Qin, R., Qian, H., Shao, C., Sun, B., Sun, Y., Tao, M., Tian, B., Wang, H., Wang, J., Wang, L., Wang, W., Wang, W., Zhang, J., Zhao, G., Zhou, J., Yu, X."The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)". International Journal of Oncology 48, no. 3 (2016): 900-907. https://doi.org/10.3892/ijo.2015.3316